Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (2025)
15 slides from Orion Oyj Class A's investor day presentation, 2025
Slide 1: Innovative Medicines and Research & Development
Innovative Medicines and Research & Development Outi Vaarala Executive Vice President
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Some highlights from the past few years - Nubeqa and opevesostat continue to drive growth
Some highlights from the past few years - Nubeqa® and opevesostat continue to drive growth • 2019-2020: First Nubeqa® launches in nmCRPC Net sales 498 (EUR million) 60 • 2021: Positive read-out from ARASENS Phase III in mHSPC with darolutamide+ADT+docetaxel 70 • 2022-2023: First Nubeqa® launches in
Slide 4: Darolutamide phase 3 trials covering almost all prostate cancer stages
Darolutamide phase 3 trials covering almost all prostate cancer stages Patient progression in prostate cancer (Neo-)Adjuvant Non-metastatic Metastatic early-stage mid-stage late-stage BCR nmCRPC mHSPC mCRPC DASL-HiCaP ARASTEP ARAMIS ARASENS darolutamide + LHRHA + darolutamide + ADT external beam rad
Slide 5: Broad opevesostat development program
has a broad opevesostat development program Trial Indication Phase II Phase III Primary endpoints OMAHA1 (later-line) metastatic OS and rPFS in AR LBD mutation- (MK-5684-003) castration-resistant positive and negative patients NCT06136624 prostate cancer (mCRPC) OMAHA2a (front-line) metastatic OS an
Slide 6: R&D and Innovative Medicines - strategic aspirations
R&D and Innovative Medicines - strategic aspirations 1-2 new projects entering 5-10 new Phase III projects Long-term target to have clinical development / year over the next ~10 years commercial presence in USA R&D FOCUS AREAS ONCOLOGY PAIN Immuno- Cancer genomics Antibody drug Ion channels Neuro-im
Slide 7: Orion's R&D has strong centres of excellence
Orion’s R&D has strong centres of excellence FINLAND UNITED KINGDOM UNITED STATES Small molecules Biologics OF AMERICA Clinical Cambridge Development & Commercial ~351 New York Espoo and Turku Capabilities Nottingham 7 ~380 Nottingham ~15 Capabilities Capabilities Capabilities 1estimate of the total
Slide 8: Recent key recruitments to R&D / Innovative Medicines
Recent key recruitments to R&D / Innovative Medicines Praveen Aanur Geula Jaffe Eugene Zhukovsky Head of Therapy Area Chief Commercial Officer VP, Head of Biologics Oncology, CMO iMeds R&D New York New York Cambridge Work history Work history Work history Board-certified physician-scientist Global c
Slide 9: Orion's research pipeline
Orion’s research pipeline Therapy area Focus area Modality Research Candidate drug Oncology immuno-oncology (ODM-214) bi-specific antibody Oncology immuno-oncology (ODM-215) CAR-T cell therapy Oncology immuno-oncology (ODM-216) bi-specific antibody Pain osteoarthritis and neuropathic pain small mole
Slide 10: Orion's extended key clinical development pipeline
Orion’s extended1 key clinical development pipeline Partner/own Trial/compound Indication (or modality for pre-clinical assets) Candidate drug Phase I Phase II Phase III Registration ARANOTE (darolutamide) metastatic hormone-sensitive prostate cancer ARASTEP (darolutamide) BCR (prostate cancer) DASL
Slide 11: ODM-105 (tasipimidine) – a novel treatment for insomnia; estimated Ph2 readout in 2026
ODM-105 (tasipimidine) – a novel treatment for insomnia; estimated Ph2 readout in 2026 Why insomnia? Huge unmet need ODM-105 has potential to differentiate • Insomnia is underdiagnosed and undertreated ODM-105 expectations – aiming to • Current medications have shortcomings be first-in-class treatme
Slide 12: ODM-212 – a TEAD inhibitor with best-in-class potential in Phase 1/2
ODM-212– a TEAD inhibitor with best-in-class potential in Phase 1/2 Huge unmet need and upside potential Potential to be best-in-class Evidence of clinical benefit (tumour Efficacy • Targeted treatment in solid tumours associated with shrinkage); dose escalation studies ongoing Hippo pathway dysregu
Slide 13: ODM-212 inhibits tumour growth in NCI-H226 mesothelioma xenograft model
ODM-212 inhibits tumour growth in subcutaneous NCI-H226 mesothelioma xenograft model Dots and error bars represent mean +/- SD **p< 0.01: Two-way ANOVA and Tukey's multiple comparisons test 13 Investor Presentation © Orion Corporation
Slide 14: How Innovative Medicines is building growth
How Innovative Medicines is building growth Growth through innovation Growth through geographic expansion • Internal R&D projects are a priority • Long-term target to commercialize and expected to drive the growth in own innovations by Orion in USA long-term and APAC • Focus in oncology and pain • E
Slide 15: Za OF ae a
Za OF ae a